Abstract 3D bioprinting is emerging as a promising technology for fabricating complex tissue
constructs with tailored biological components and mechanical properties. Recent advances …

High attrition of new oncology drug candidates in clinical trials is partially caused by the poor
predictive capacity of artificial monolayer cell culture assays early in drug discovery …

The poor predictability of human liver toxicity is still causing high attrition rates of drug
candidates in the pharmaceutical industry at the non-clinical, clinical, and post-marketing …

Non-alcoholic fatty liver disease (NAFLD) represents a global healthcare challenge,
affecting 1 in 4 adults, and death rates are predicted to rise inexorably. The progressive form …

Scalable and reproducible production of 3D cellular spheroids is highly demanded, by
pharmaceutical companies, for drug screening purposes during the pre‐clinical evaluation …

Drug-induced liver injury (DILI) is a major concern for the pharmaceutical industry and
constitutes one of the most important reasons for the termination of promising drug …

One of the major mechanisms of drug-induced liver injury includes mitochondrial
perturbation and dysfunction. This is not a surprise, given that mitochondria are essential …

To date, the treatment of articular cartilage lesions remains challenging. A promising
strategy for the development of new regenerative therapies is hybrid bioprinting, combining …

Drug-induced hepatotoxicity is a leading cause of drug withdrawal from the market. High-
throughput screening utilizing in vitro liver models is critical for early-stage liver toxicity …

Cancer still ranks as a leading cause of mortality worldwide. Although considerable efforts
have been dedicated to anticancer therapeutics, progress is still slow, partially due to the …